Search Results for "rituximab"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for rituximab. Results 41 to 44 of 44 total matches.
See also: Rituxan
Obeticholic Acid (Ocaliva) for Primary Biliary Cholangitis
The Medical Letter on Drugs and Therapeutics • Mar 27, 2017 (Issue 1517)
, methotrexate, rituximab, fibrates, and
other drugs have been added to UDCA when monotherapy
fails ...
Obeticholic acid (Ocaliva – Intercept), a farnesoid X
receptor agonist, has been approved by the FDA for
treatment of primary biliary cholangitis; it is indicated
for use in combination with ursodeoxycholic acid
(ursodiol, UDCA; Urso, and others) in adults with an
inadequate response to UDCA and as monotherapy in
adults unable to tolerate UDCA. Obeticholic acid is the
second drug to be approved for this indication; UDCA
was the first.
Seladelpar (Livdelzi) for Primary Biliary Cholangitis
The Medical Letter on Drugs and Therapeutics • Jan 20, 2025 (Issue 1720)
, and rituximab have also been tried, but
their benefits are unclear.
Obeticholic acid (Ocaliva), a farnesoid X ...
Seladelpar (Livdelzi – Gilead), a peroxisome
proliferator-activated receptor (PPAR)-delta agonist,
has received accelerated approval from the FDA for use
in combination with ursodeoxycholic acid (ursodiol,
UDCA; Urso Forte, and generics) for treatment of
primary biliary cholangitis (PBC) in adults who had an
inadequate response to UDCA and as monotherapy in
those unable to tolerate UDCA. Accelerated approval
was based on a reduction in alkaline phosphatase
(ALP) levels. Seladelpar is the second PPAR agonist
to be approved in the US for this indication; elafibranor
(Iqirvo)...
Med Lett Drugs Ther. 2025 Jan 20;67(1720):13-5 doi:10.58347/tml.2025.1720d | Show Introduction Hide Introduction
Drugs of Choice for Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • Mar 31, 1995 (Issue 945)
; Rituximab
Cladribine; interferon alfa; etoposide;
High-dose chemotherapy + bone marrow or
peripheral ...
Intravenous Immunoglobulin (IVIG)
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006 (Issue 1249)
Ahmed et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J ...
Intravenous immunoglobulin (IVIG) has 6 FDA approved indications and is prescribed off-label for many others. How many of these uses are justified is controversial.